This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Cialis

Eli Lilly & Company

Drug Names(s): LY450190, Zalutia (Japan), Adcirca

Description: BioMedTracker has separate drug profiles for tadalafil. Please also see Adcirca for the pulmonary arterial hypertension (PAH) indication.

Tadalafil is an oral PDE5 inhibitor.

Deal Structure: ICOS and Eli Lilly
In October 1998, ICOS and Lilly formed Lilly ICOS, which is 50/50-owned, to develop and commercialize PDE5 inhibitors. Both Lilly and ICOS will market any products resulting from the collaboration.

Lilly ICOS intends to commercialize products approved in North America and Europe through the services of both ICOS and Lilly. For countries outside the European Union and North America, in exchange for royalty payments, Lilly ICOS has granted Lilly an exclusive license to develop, manufacture and commercialize the PDE5 inhibitors developed in the collaboration.

Under the terms of this arrangement, ICOS received a $75.0 million payment upon formation of the joint venture, a $15.0 million payment in 1999 upon initiation of a Phase 3 clinical trial program for Cialis and an additional $15.0 million payment in 2001 following the filing of the NDA with the FDA. Lilly ICOS was initially capitalized by Lilly through cash contributions and Icos'...See full deal structure in Biomedtracker

Partners: Sanofi Nippon Shinyaku Co., Ltd.


Cialis News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug